Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2004 1
2005 2
2006 2
2007 2
2008 1
2010 2
2011 4
2012 4
2013 3
2014 3
2015 3
2016 1
2017 2
2018 1
2019 1
2020 2
2021 1
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
T-cell receptor diversity as a prognostic biomarker in melanoma patients.
Charles J, Mouret S, Challende I, Leccia MT, De Fraipont F, Perez S, Plantier N, Plumas J, Manuel M, Chaperot L, Aspord C. Charles J, et al. Among authors: mouret s. Pigment Cell Melanoma Res. 2020 Jul;33(4):612-624. doi: 10.1111/pcmr.12866. Epub 2020 Feb 3. Pigment Cell Melanoma Res. 2020. PMID: 31971658
Unique CLR expression patterns on circulating and tumor-infiltrating DC subsets correlated with clinical outcome in melanoma patients.
Sosa Cuevas E, Valladeau-Guilemond J, Mouret S, Roubinet B, de Fraipont F, Landemarre L, Charles J, Bendriss-Vermare N, Chaperot L, Aspord C. Sosa Cuevas E, et al. Among authors: mouret s. Front Immunol. 2022 Oct 24;13:1040600. doi: 10.3389/fimmu.2022.1040600. eCollection 2022. Front Immunol. 2022. PMID: 36353633 Free PMC article.
Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1-)-pDC subset negatively correlated with clinical outcomes in melanoma patients.
Sosa Cuevas E, Bendriss-Vermare N, Mouret S, De Fraipont F, Charles J, Valladeau-Guilemond J, Chaperot L, Aspord C. Sosa Cuevas E, et al. Among authors: mouret s. Clin Transl Immunology. 2022 May 3;11(5):e1382. doi: 10.1002/cti2.1382. eCollection 2022. Clin Transl Immunology. 2022. PMID: 35517992 Free PMC article.
Serum IGF1 Is a Prognostic Marker for Resistance to Targeted Therapies and a Predictive Marker for Anti-IGF1 Receptor Therapy in Melanoma.
Castillo-Ferrer C, Marguet T, Vanwonterghem L, Erbek S, Chuffart F, Mouret S, Messai ST, Gauchez AS, Coll JL, Charles J, Hurbin A, Martel-Frachet V. Castillo-Ferrer C, et al. Among authors: mouret s. J Invest Dermatol. 2024 Feb;144(2):422-426.e8. doi: 10.1016/j.jid.2023.07.016. Epub 2023 Aug 12. J Invest Dermatol. 2024. PMID: 37580013 No abstract available.
38 results